RxSight Inc. (RXST) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

RxSight Inc. (RXST)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

30.09

-0.63 (-2.05%)

At close: Jan 14, 2025, 3:59 PM

30.08

-0.05%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	29.11
Market Cap	1.21B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.81
PE Ratio (ttm)	-37.15
Forward PE	n/a
Analyst	Buy

Ask	36.69
Volume	571,468
Avg. Volume (20D)	681,970
Open	30.88
Previous Close	30.72
Day's Range	29.14 - 31.43
52-Week Range	26.29 - 66.54
Beta	undefined

About RXST

RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment dev...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Jul 30, 2021

Employees 374

Stock Exchange NASDAQ

Ticker Symbol RXST

Website https://www.rxsight.com

Analyst Forecast

According to 8 analyst ratings, the average rating for RXST stock is "Buy." The 12-month stock price forecast is $63.5, which is an increase of 111.00% from the latest price.

Buy 75.00%

Hold 25.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

RxSight Inc. is scheduled to release its earnings on Feb 26, 2025, during market hours.
Analysts project revenue of $40.12M, reflecting a 40.38% YoY growth and earnings per share of -0.17, making a 30.77% increase YoY.

Why Price Moved

1 day ago · Source New

-8.11%

RxSight shares are trading lower after Stifel cut ... Unlock content with Pro Subscription

3 weeks ago · Source

-11.86%

RxSight shares are trading lower after Stifel downgraded the stock from Buy to Hold and cut its price target from $65 to $40.

News

3 weeks ago · https://thefly.com

RxSight downgraded to Hold from Buy at Stifel

Stifel downgraded RxSight (RXST) to Hold from Buy with a price target of $40, down from $65. The firm's latest deep-dive survey of surgeons leads to believe that the risk from U.S. premium IOL - intra...

4 weeks ago · https://thefly.com

Needham ups Alcon target, adds to Conviction List

Needham earlier today raised the firm's price target on Alcon (ALC) to $108 from $103 and kept a Buy rating on the shares. The firm also added the stock to its Conviction List, replacing RxSight (RXST...

1 month ago · seekingalpha.com

RxSight's Momentum In The Large Cataract Surgery Market Merits A Close Eye

RxSight's light adjustable lenses [LAL] continue to gain traction in the $6 billion-plus cataract surgical market. In their Q3 earnings report, RxSight announced that 24,554 LALs were sold in Q3, repr...

1 month ago · zacks.com

RxSight (RXST) Upgraded to Buy: Here's What You Should Know

RxSight (RXST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · seekingalpha.com

RxSight, Inc. (RXST) Q3 2024 Earnings Call Transcript

RxSight, Inc. (NASDAQ:RXST ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Oliver Moravcevic - Vice President, Investor Relations Ron Kurtz - President, Chief Execu...

2 months ago · zacks.com

RxSight, Inc. (RXST) Reports Break-Even Earnings for Q3

RxSight, Inc. (RXST) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.35 per share a year ago.